



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic)

kallistatin (h): 293 Lysate: sc-158652

BACKGROUND

Kallistatin, also known as serpin A4, kallikrein inhibitor and protease inhibitor 4 (PI4), is a member of the serpin family and was first identified as a kallikrein-binding protein. It is expressed in vascular smooth muscle cells and endothelial cells. Kallistatin functions as a serine proteinase inhibitor and a heparin-binding protein and is involved in blood pressure regulation, vasculature relaxation, protection against inflammation and stimulation of neointima hyperplasia. It also acts as a negative regulator of angiogenesis by blocking the cellular response to VEGF and bFGF heparin binding proteins (two major angiogenic stimulators). Kallistatin may compete with VEGF and bFGF binding to heparin-sulfate proteoglycans via its heparin binding domain. In addition, its anti-angiogenesis and anti-inflammatory activity may play an important role in the inhibition of tumor growth and arthritis.

REFERENCES

1. Zhou, G.X., et al. 1993. Kallistatin: a novel human tissue kallikrein inhibitor. Purification, characterization and reactive center sequence. *J. Biol. Chem.* 267: 25873-25880.
2. Chao, J., et al. 1997. Tissue kallikrein inhibitors in mammals. *Immunopharmacology* 32: 67-72.
3. Miao, R.Q., et al. 2002. Kallistatin is a new inhibitor of angiogenesis and tumor growth. *Blood* 100: 3245-3252.
4. Thongboonkerd, V. and Malasit, P. 2005. Renal and urinary proteomics: current applications and challenges. *Proteomics* 5: 1033-1042.
5. Devani, M., et al. 2005. Kallikrein-kinin system in inflammatory bowel diseases: Intestinal involvement and correlation with the degree of tissue inflammation. *Dig. Liver Dis.* 37: 665-673.
6. Wang, C.R., et al. 2005. Prophylactic adenovirus-mediated human kallistatin gene therapy suppresses rat arthritis by inhibiting angiogenesis and inflammation. *Arthritis Rheum.* 52: 1319-1324.
7. Luo, L.Y. and Jiang, W. 2006. Inhibition profiles of human tissue kallikreins by serine protease inhibitors. *Biol. Chem.* 387: 813-816.
8. Chao, J., et al. 2007. Novel role of kallistatin in protection against myocardial ischemia-reperfusion injury by preventing apoptosis and inflammation. *Hum. Gene Ther.* 17: 1201-1213.
9. Luo, Q., et al. 2007. Altered protein expression at early-stage rat hepatic neoplasia. *Am. J. Physiol. Gastrointest. Liver Physiol.* 292: G1272-G1282.

CHROMOSOMAL LOCATION

Genetic locus: SERPINA4 (human) mapping to 14q32.13.

PRODUCT

kallistatin (h): 293 Lysate represents a lysate of human kallistatin transfected 293 cells and is provided as 100 µg protein in 200 µl SDS-PAGE buffer.

STORAGE

Store at -20° C. Repeated freezing and thawing should be minimized. Sample vial should be boiled once prior to use. Non-hazardous. No MSDS required.

APPLICATIONS

kallistatin (h): 293 Lysate is suitable as a Western Blotting positive control for human reactive kallistatin antibodies. Recommended use: 10-20 µl per lane.

Control 293 Lysate: sc-110760 is available as a Western Blotting negative control lysate derived from non-transfected 293 cells.

RESEARCH USE

For research use only, not for use in diagnostic procedures.

PROTOCOLS

See our web site at www.scbt.com for detailed protocols and support products.